{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:10Z","timestamp":1790929930748,"version":"4.1.0"},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>Rituximab selectively targets the B\u2010cell compartment, including rheumatoid factor\u2010positive B cells. Short\u2010term efficacy and safety of rituximab in rheumatoid arthritis (RA) has been established by multicenter randomized placebo\u2010controlled studies. Results of long\u2010term follow\u2010up of the phase II\/III clinical trials have confirmed the efficacy and safety of repeated courses of rituximab in the responders. However, mechanisms of action in humans, retreatment regimens, biologic effects on memory B cells and on immunoglobulin levels of prolonged exposure of the immune system to B\u2010cell depletion over time, and pharmacogenetic aspects remain open and intriguing issues of rituximab therapy. Several studies are ongoing to clarify possible clinical and biologic predictors of response to rituximab in RA and in other autoimmune diseases where rituximab has been proven to be effective. Preliminary clinical and pharmacogenetic results of our cohort of RA patients managed with rituximab from the year 2000 are presented.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2009.04668.x","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T22:02:36Z","timestamp":1251842556000},"page":"692-700","source":"Crossref","is-referenced-by-count":21,"title":["Long\u2010Term Effects of Rituximab in Rheumatoid Arthritis"],"prefix":"10.1111","volume":"1173","author":[{"given":"Luca","family":"Quartuccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Masolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Saracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pellerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.02.004"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.002"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.01.011"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.11.030"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff M.E.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.2.205"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10467"},{"issue":"9","key":"e_1_2_7_11_2","first-page":"S131","article-title":"Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis","volume":"52","author":"Fleischmann R.M.","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"9","key":"e_1_2_7_12_2","first-page":"S341","article-title":"Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis","volume":"52","author":"Emery P.","year":"2005","journal-title":"Arthritis Rheum."},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2856"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel004"},{"key":"e_1_2_7_15_2","first-page":"S430","article-title":"Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease\u2010modifying anti\u2010rheumatic drugs","volume":"66","author":"Emery P.","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_7_16_2","first-page":"S432","article-title":"Repeated treatment courses of rituximab in rheumatoid arthritis: sustained efficacy in patients with inadequate response to one or more TNF inhibitors","volume":"66","author":"Keystone E.","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_7_17_2","first-page":"88","article-title":"Extended follow\u2010up of long\u2010term safety of rituximab in rheumatoid arthritis","volume":"66","author":"Van Vollenhoven R.","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23059"},{"key":"e_1_2_7_19_2","first-page":"S149","article-title":"Immunoglobulin levels and infection rates in patients with rheumatoid arthritis treated with repeated courses of rituximab","volume":"56","author":"Genovese M.","year":"2007","journal-title":"Arthritis Rheum."},{"key":"e_1_2_7_20_2","first-page":"S300","article-title":"Long\u2010term safety of rituximab: 6\u2010year follow\u2010up of the RA clinical trial and re\u2010treatment population","volume":"58","author":"Van Vollenhoven R.F.","year":"2008","journal-title":"Arthritis Rheum."},{"key":"e_1_2_7_21_2","first-page":"S303","article-title":"Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: REFLEX study","volume":"58","author":"Cohen S.","year":"2008","journal-title":"Arthritis Rheum."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel393"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200305000-00011"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.8.4710"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.221"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103223441207"},{"issue":"9","key":"e_1_2_7_27_2","first-page":"S289","article-title":"B\u2010cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: transient recirculation of plasmablasts and increased level of germinal center founder cell","volume":"52","author":"Roll P.","year":"2005","journal-title":"Arthritis Rheum."},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21617"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1731"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23473"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23902"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080960"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0300-9475.2004.01441.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2004.01.006"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10467"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.04.012"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079954"},{"key":"e_1_2_7_38_2","first-page":"610","article-title":"Long\u2010term response to rituximab in 36 patients with rheumatoid arthritis: a single centre experience","volume":"67","author":"Quartuccio L.","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30156"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040119"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052283"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2862"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10764"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-006-0057-9"},{"key":"e_1_2_7_47_2","first-page":"1245","article-title":"B cell\u2010targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application","volume":"35","author":"Mease P.J.","year":"2008","journal-title":"J. Rheumatol."},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.817"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.168"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel174"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520701452225"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0346"},{"key":"e_1_2_7_54_2","first-page":"S710","article-title":"Belimumab (BmAb), a fully human monoclonal antibody to B\u2010lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population","volume":"52","author":"McKay J.","year":"2005","journal-title":"Arthritis Rheum."},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21650"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2009.04668.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2009.04668.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T07:39:58Z","timestamp":1695627598000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2009.04668.x"}},"subtitle":["Clinical, Biologic, and Pharmacogenetic Aspects"],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1749-6632.2009.04668.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04668.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}